This blog post was first published in the Hartford Courant on September 15, 2024 by Arden Parrish under the title: Opinion: The insulin crisis is far from over. Public pharma could be the solution. Read more
T1International is pleased to announce that Shaina Kasper has been appointed as the new Executive Director. Shaina succeeds Elizabeth “Liz” Pfiester, the organization’s Founder and Executive Director since 2013, who established T1International as a force for change in the fight against insulin price gouging and for the rights of people living with type 1 diabetes. Read more
Ten years ago, when I was first diagnosed with type one diabetes, I spent countless hours studying my newly diagnosed condition. I came across a research paper by Stanford University stating that people living with type 1 diabetes make around 180 more decisions per day than people without diabetes, with a rate of an extra decision every 5 minutes of waking time. I then realised that type 1 diabetes is a full-time job, without vacations or time off. Read more
The idea to work on this issue stemmed from a personal experience that deeply impacted me. In 2008, I lost my aunt to diabetes-related complications. Witnessing her struggle with diabetes and the lack of medical expertise to detect and manage her condition was a profound and heartbreaking experience for me. Read more
This blog post was first published in Bridge Michigan on May 28, 2024 by Quinn Nichols, Nicole Koonce, and Allison Hardt under the title: Michigan has a chance to learn from California’s public pharma initiative. Read more
T1International and other organisations shared a letter today with Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, urging that the World Health Organization reject any funding directly or indirectly from the pharmaceutical industry. The entity already rejects funding from the tobacco and formula milk industry. The letter also asks WHO to push the pharmaceutical industry to lower prices and create sustainable solutions, and to practise more transparency and accountability to the global community that the entity exists to serve. Read more
Over the past few months, people with type 1 diabetes around the globe have been going from pharmacy to pharmacy in search of insulin. There have been insulin shortages in many different countries. For people living with type 1 diabetes, insulin is as important as oxygen and people need a consistent supply. Insulin shortages can lead to irreversible complications and even death. Read more
We are writing to propose WHO action items aimed at addressing meaningful engagement with people living with diabetes in the global coverage targets for diabetes. Read more
T1International advocates, Jesús Morales Sánchez (Communities of Color Working Group Co-Leader), Kristen Whitney Daniels (Federal Working Group Co-Leader), Lib Gatti (USA Advocacy Manager), and Shaina Kasper (Policy and Advocacy Director), were honored to be invited to a recent event at the White House focused on lowering healthcare costs. The event celebrated the success of the access to medicines movement in achieving a $35 monthly cap on out-of-pocket costs for insulin for Medicare Part D beneficiaries, allowing Medicare to negotiate drug prices directly with pharmaceutical companies, and more. Read more
On March 16, 2024, hundreds of #insulin4all advocates participated in over a dozen events across the globe calling for insulin access and affordability as part of the Global Day of Action for #insulin4all, sharing their stories on the critical need for insulin equity now. Read more